Breast Cancer Research and Treatment

, Volume 100, Issue 3, pp 263–271

Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: NCIC CTG Trial MA.19

  • Jianhua Liu
  • Dongsheng Tu
  • Janet Dancey
  • Leonard Reyno
  • Kathleen I. Pritchard
  • Joseph Pater
  • Lesley K Seymour
Clinical Trial

DOI: 10.1007/s10549-006-9257-1

Cite this article as:
Liu, J., Tu, D., Dancey, J. et al. Breast Cancer Res Treat (2006) 100: 263. doi:10.1007/s10549-006-9257-1

Abstract

Background

DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer. However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).

Methods

Standard National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) approaches were applied as the primary method to analyze the QOL data from this trial. This includes cross-sectional comparisons, together with a global test for the QOL response rate. Sensitivity analyses were also performed for selected QOL domains and items, using other types of summary measures and statistics.

Results

Two hundred seventy one patients (89% of randomized) submitted the baseline QOL questionnaires and were included in the QOL analysis. No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04). Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm. Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.

Conclusion

Different analyses yielded slightly different conclusions but, in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and␣better QOL. Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.

Keywords

Quality of lifeAnalysesStatistical methodsDPPEBreast cancerTesmilifene

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Jianhua Liu
    • 1
  • Dongsheng Tu
    • 1
  • Janet Dancey
    • 1
  • Leonard Reyno
    • 1
  • Kathleen I. Pritchard
    • 1
  • Joseph Pater
    • 1
  • Lesley K Seymour
    • 1
  1. 1.National Cancer Institute of Canada Clinical Trials GroupCancer Research Institute, Queens UniversityKingstonCanada